Resverlogix Corp. (TSX:RVX) is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. Apabetalone is the first therapy of its kind to have been granted US FDA Breakthrough Therapy Designation – for a major cardiovascular indication – to help facilitate a time-efficient drug development program including planned clinical trials and plans for expediting the manufacturing development strategy.
Co-founder, President and CEO
Donald McCaffrey is co-founder, President and CEO of Resverlogix Corp. Don has 40 years of corporate management experience including 20 years in drug discovery & development. Don is also the co-founder, President and CEO of Zenith Epigenetics, a private, clinical stage biotechnology company focused on novel cancer therapeutics.